The potential protective role of corticosteroid therapy in patients with asthma and COPD against COVID-19.
Asthma
COPD
COVID-19
Corticosteroids
Hospitalization
Pulmonary diseases
Journal
Clinical and molecular allergy : CMA
ISSN: 1476-7961
Titre abrégé: Clin Mol Allergy
Pays: England
ID NLM: 101152195
Informations de publication
Date de publication:
01 Nov 2021
01 Nov 2021
Historique:
received:
30
07
2021
accepted:
02
10
2021
entrez:
1
11
2021
pubmed:
2
11
2021
medline:
2
11
2021
Statut:
epublish
Résumé
The observation of patients hospitalized for coronavirus disease (COVID-19) led us to note a lower prevalence of patients affected by chronic respiratory disease, in particular asthmatic patients, compared to the general population. Therefore, the aim of this paper is to evaluate the possible protective role of corticosteroid therapy in patients with chronic lung disease, regarding the risk of contracting severe COVID-19. SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) receptors to enter the cells. Considering the high number of these receptors in patients affected by asthma and chronic obstructive pulmonary disease (COPD), the evidence that these patients do not have a high risk of hospitalization for COVID-19 needs further study to understand what the possible protective "factors" are in these patients. In particular, the finding in some studies of reduced coronavirus replication in cell lines treated with steroids, molecules commonly used for treating chronic lung diseases, needs further attention. The hypothesis that corticosteroids, commonly used in treating airways diseases, might modify the severity of SARS-CoV-2 disease has become a key point and a possible predictive factor of a positive outcome of COVID-19 in patients treated everyday with these molecules.
Sections du résumé
BACKGROUND
BACKGROUND
The observation of patients hospitalized for coronavirus disease (COVID-19) led us to note a lower prevalence of patients affected by chronic respiratory disease, in particular asthmatic patients, compared to the general population. Therefore, the aim of this paper is to evaluate the possible protective role of corticosteroid therapy in patients with chronic lung disease, regarding the risk of contracting severe COVID-19.
MAIN BODY
METHODS
SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) receptors to enter the cells. Considering the high number of these receptors in patients affected by asthma and chronic obstructive pulmonary disease (COPD), the evidence that these patients do not have a high risk of hospitalization for COVID-19 needs further study to understand what the possible protective "factors" are in these patients. In particular, the finding in some studies of reduced coronavirus replication in cell lines treated with steroids, molecules commonly used for treating chronic lung diseases, needs further attention.
SHORT CONCLUSION
CONCLUSIONS
The hypothesis that corticosteroids, commonly used in treating airways diseases, might modify the severity of SARS-CoV-2 disease has become a key point and a possible predictive factor of a positive outcome of COVID-19 in patients treated everyday with these molecules.
Identifiants
pubmed: 34719394
doi: 10.1186/s12948-021-00159-4
pii: 10.1186/s12948-021-00159-4
pmc: PMC8557959
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
19Subventions
Organisme : siaaic
ID : JS-SIAA-CMAL-0320
Informations de copyright
© 2021. The Author(s).
Références
Antimicrob Agents Chemother. 2020 Jun 23;64(7):
pubmed: 32366720
Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1816-22
pubmed: 11734429
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
Nat Immunol. 2016 Jan;17(1):65-75
pubmed: 26595887
Front Pharmacol. 2020 Sep 09;11:571156
pubmed: 33013412
Eur Respir J. 2021 Mar 4;57(3):
pubmed: 32978309
Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1244-L1247
pubmed: 32401670
Sci Rep. 2014 Nov 24;4:7176
pubmed: 25417801
J Allergy Clin Immunol. 2020 Sep;146(3):541-542
pubmed: 32620309
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Infection. 2019 Jun;47(3):377-385
pubmed: 30298471
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
Eur Respir J. 2020 May 7;55(5):
pubmed: 32341100
Am J Respir Crit Care Med. 2020 Jul 1;202(1):8-10
pubmed: 32437628
Allergy. 2015 Aug;70(8):910-20
pubmed: 25858686
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Lancet Respir Med. 2021 Aug;9(8):909-923
pubmed: 33812494
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Lancet Respir Med. 2020 Nov;8(11):1106-1120
pubmed: 32979987
Respir Investig. 2020 May;58(3):155-168
pubmed: 32094077
Eur Respir J. 2021 Mar 4;57(3):
pubmed: 33154029
Nat Med. 2006 Sep;12(9):1023-6
pubmed: 16906156
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Expert Rev Respir Med. 2021 Apr;15(4):561-568
pubmed: 33183113
Am J Respir Crit Care Med. 2014 Dec 15;190(12):1373-82
pubmed: 25350863
Int Immunopharmacol. 2019 Dec;77:105950
pubmed: 31629940
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Eur Respir J. 2014 Dec;44(6):1666-81
pubmed: 25234802
Respir Med. 2020 Aug - Sep;170:106045
pubmed: 32843175
Nat Commun. 2018 Jun 8;9(1):2229
pubmed: 29884817
Pulm Pharmacol Ther. 2015 Feb;30:44-50
pubmed: 25445928
J Asthma. 2021 Apr 1;:1-14
pubmed: 33556287
Respir Med. 2021 Jan;176:106261
pubmed: 33260107